---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004981"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:20:51.980499+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences Reports Positive Preclinical Results for Simufilam in TSC-Related Epilepsy Model

## Summary
- Simufilam attenuated seizure progression with significant dose-response in Tsc1 conditional knockout mouse model of TSC-related epilepsy.
- Study conducted in collaboration with TSC Alliance and TSC Preclinical Consortium, executed by PsychoGenics, Inc.
- First clinical proof-of-concept study for simufilam in TSC-related epilepsy is expected to begin in H1 2026.
- Results consistent with prior findings published in Science Translational Medicine from Yale School of Medicine.

## SEC filing metadata
- accession: 0001171843-25-004981
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184325004981/0001171843-25-004981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184325004981/f8k_080425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004981
- JSON: https://secwatch.observer/filing/0001171843-25-004981.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.